APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

Creative Commons License

Lau G., Yu M., Wong G., Thompson A., Ghazinian H., Hou J., ...Daha Fazla

HEPATOLOGY INTERNATIONAL, cilt.15, sa.5, ss.1031-1048, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 5
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1007/s12072-021-10239-x
  • Dergi Adı: HEPATOLOGY INTERNATIONAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1031-1048
  • Anahtar Kelimeler: APASL, Hepatitis B reactivation, Immunosuppressive therapy, Guideline, VIRUS HBV REACTIVATION, BONE-MARROW-TRANSPLANTATION, STEM-CELL TRANSPLANTATION, ACTING ANTIVIRAL THERAPY, PREEMPTIVE LAMIVUDINE, RHEUMATOID-ARTHRITIS, LYMPHOMA PATIENTS, POSITIVE PATIENTS, SURFACE-ANTIGEN, CANCER-PATIENTS
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Ankara Üniversitesi Adresli: Evet

Özet

Background & Aim Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical practice guidelines aim to assist clinicians in all disciplines involved in the use of immunosuppressive therapy to effectively prevent and manage hepatitis B reactivation. Methods All publications related to hepatitis B reactivation with the use of immunosuppressive therapy since 1975 were reviewed. Advice from key opinion leaders in member countries/administrative regions of Asian-Pacific Association for the study of the liver was collected and synchronized. Immunosuppressive therapy was risk-stratified according to its reported rate of hepatitis B reactivation. Recommendations We recommend the necessity to screen all patients for hepatitis B prior to the initiation of immunosuppressive therapy and to administer pre-emptive nucleos(t)ide analogues to those patients with a substantial risk of hepatitis and acute-on-chronic liver failure due to hepatitis B reactivation.